Companion Diagnostics
•52 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (52)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
Companion Diagnostics tests are used to identify patients most likely to respond to targeted therapies.
|
$454.86B |
$188.88
-0.09%
|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides companion diagnostics (e.g., Oncomine Dx tests) that inform targeted therapies.
|
$214.25B |
$567.41
+2.01%
|
|
ZTS
Zoetis Inc.
Zoetis develops companion diagnostics to identify likely responders to therapies, aligning with Companion Diagnostics.
|
$64.15B |
$144.07
+0.33%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$50.63B |
$631.32
+0.44%
|
|
BIIB
Biogen Inc.
Potential blood-based diagnostics/companion diagnostics to support LEQEMBI and other therapies.
|
$22.62B |
$154.27
+3.11%
|
|
LH
Labcorp Holdings Inc.
Labcorp’s biomarker-based diagnostics/supporting therapy selection aligns with companion diagnostics.
|
$21.10B |
$253.95
+0.64%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$12.20B |
$64.69
+2.33%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$11.60B |
$93.05
+0.69%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$10.49B |
$46.85
+1.13%
|
|
LNTH
Lantheus Holdings, Inc.
Pipeline includes companion diagnostics elements (imaging-based biomarkers paired with therapies), indicating companion diagnostic activity.
|
$3.99B |
$57.70
+3.97%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$3.93B |
$136.83
+4.05%
|
|
CELC
Celcuity Inc.
Celcuity's CELsignia platform implies a companion diagnostics capability to identify patients likely to respond to gedatolisib.
|
$2.92B |
$77.24
-2.18%
|
|
VCYT
Veracyte, Inc.
Tests function as companion diagnostics to identify patients most likely to benefit from specific therapies.
|
$2.83B |
$36.10
+2.19%
|
|
IDYA
IDEAYA Biosciences, Inc.
Emphasizes companion diagnostics to identify patients most likely to respond to therapies.
|
$2.79B |
$31.87
+0.85%
|
|
NEO
NeoGenomics, Inc.
MRD-related diagnostics and companion diagnostics align with therapy selection and monitoring.
|
$1.26B |
$9.78
+0.88%
|
|
OPK
OPKO Health, Inc.
OPKO's diagnostics includes biomarker-based tests (e.g., 4Kscore) that align with companion/biomarker diagnostics.
|
$1.08B |
$1.34
-7.88%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$851.45M |
$9.61
+1.05%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$741.11M |
$8.04
+1.07%
|
|
CSTL
Castle Biosciences, Inc.
Tests act as biomarker-based diagnostic tools that inform treatment decisions, fitting the Companion Diagnostics category.
|
$736.24M |
$25.52
+5.41%
|
|
FLGT
Fulgent Genetics, Inc.
Companion diagnostics to guide targeted therapies.
|
$683.46M |
$22.44
-0.62%
|
|
VSTM
Verastem, Inc.
Partnership to develop a companion diagnostic test for AVMAPKI FAKZYNJA CO-PACK aligns with 'Companion Diagnostics'.
|
$519.27M |
$9.45
+2.33%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Development of companion diagnostics for GD2 expression to select patients.
|
$389.89M |
$8.61
|
|
ANRO
Alto Neuroscience, Inc.
Biomarker-based companion diagnostics approach to select patients most likely to respond to Alto's therapies.
|
$384.15M |
$14.18
-0.98%
|
|
ACIU
AC Immune S.A.
Companion Diagnostics – biomarker-based tests to identify patients most likely to respond to targeted therapies.
|
$337.46M |
$3.38
|
|
SOPH
SOPHiA GENETICS S.A.
Companion Diagnostics: enables biomarker-driven diagnostic support for therapy selection.
|
$332.19M |
$4.95
-4.62%
|
|
XGN
Exagen Inc.
Exagen's biomarker-based tests (e.g., AVISE CTD, SLE T-cell markers, RA33) align with companion diagnostics.
|
$210.09M |
$11.67
-0.77%
|
|
CATX
Perspective Therapeutics, Inc.
Imaging companion diagnostics context via 203Pb imaging to guide therapy.
|
$202.64M |
$2.73
+3.22%
|
|
GNFT
Genfit S.A.
NIS4 is a blood-based diagnostic test for identifying at-risk NASH patients, aligning with biomarker-based diagnostics.
|
$192.64M |
$3.89
-8.25%
|
|
IMDX
Insight Molecular Diagnostics Inc.
GraftAssureDx functions as a biomarker-based diagnostic that could be viewed as a Companion Diagnostics offering.
|
$171.88M |
$6.06
+2.28%
|
|
BNR
Burning Rock Biotech Limited
MCED and MRD diagnostics function as biomarker-based tests aligned with companion diagnostics use.
|
$138.94M |
$13.56
+9.44%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is developing a companion diagnostic to identify Cyclin E1–positive patients likely to respond to azenosertib.
|
$107.93M |
$1.49
+0.34%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$62.40M |
$2.00
+2.84%
|
|
BDSX
Biodesix, Inc.
Biodesix' biomarker-based tests support biomarker-driven therapy selection, i.e., companion diagnostics themes.
|
$50.05M |
$6.98
+6.24%
|
|
FGEN
FibroGen, Inc.
FG-3180 is a companion imaging agent paired with FG-3246, aligning with Companion Diagnostics.
|
$44.94M |
$11.12
+0.72%
|
|
VNRX
VolitionRx Limited
Nu.Q Discover and Nu.Q Cancer positioning create companion diagnostic opportunities and biomarker-driven patient stratification.
|
$44.71M |
$0.43
-1.68%
|
|
RADX
Radiopharm Theranostics Limited
Companion diagnostics strategy through diagnostic radiotracers and imaging assets.
|
$34.73M |
$5.30
+2.51%
|
|
BOLD
Boundless Bio, Inc.
The company utilizes ECHO, a diagnostic test to identify ecDNA-driven cancers, functioning as a Companion Diagnostics offering.
|
$31.34M |
$1.39
+0.36%
|
|
ALLR
Allarity Therapeutics, Inc.
DRP platform functions as a companion diagnostic to identify patients likely to respond to stenoparib and other therapies.
|
$21.87M |
$1.44
+2.86%
|
|
PRPH
ProPhase Labs, Inc.
BE-Smart uses a biomarker-based diagnostic panel, aligning with companion diagnostics.
|
$15.11M |
$0.36
-1.51%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$13.43M |
$4.92
+0.72%
|
|
PALI
Palisade Bio, Inc.
The company plans companion diagnostic biomarker tests to select likely responders for PALI-2108, fitting Companion Diagnostics.
|
$9.93M |
$2.06
+6.19%
|
|
RNAZ
TransCode Therapeutics, Inc.
Diagnostic assays for measuring microRNA-10b could function as companion diagnostics to guide therapy.
|
$9.34M |
$11.18
+2.10%
|
|
APM
Aptorum Group Limited
APOE Genotyping test functions as a companion diagnostic to guide therapy selection and clinical trial enrollment.
|
$7.88M |
$1.45
-1.70%
|
|
BMRA
Biomerica, Inc.
Companion Diagnostics capability for biomarker-based patient stratification in therapy/diet guided approaches.
|
$7.85M |
$2.74
-0.72%
|
|
TRIB
Trinity Biotech plc
Includes companion diagnostics/biomarker-guided tests as part of its oncology-focused diagnostic portfolio.
|
$7.67M |
$1.02
+2.00%
|
|
POAI
Predictive Oncology Inc.
Companion diagnostics capability via ChemoFx assay expansion to identify patients most likely to respond to therapies.
|
$5.31M |
$8.78
+3.72%
|
|
IDXG
Interpace Biosciences, Inc.
Tests used to identify patients most likely to respond to specific cancer therapies, i.e., companion diagnostics.
|
$4.12M |
$1.02
|
|
ADIL
Adial Pharmaceuticals, Inc.
ADIL's strategy includes a companion diagnostic genetic test to identify responders, aligning with Companion Diagnostics.
|
$2.76M |
$0.34
-5.44%
|
|
CANF
Can-Fite BioPharma Ltd.
Development of a blood-based biomarker test kit for A3AR supports companion diagnostic capabilities.
|
$2.12M |
$0.42
-1.61%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Diagnostics is developing pretreatment diagnostic tests for prostate cancer (PC-RAD) and theranostics, aligning with companion diagnostics.
|
$1.30M |
$3.00
-1.64%
|
|
LADX
LadRx Corporation
LadRx developed a companion diagnostic (ACDx) to identify patients likely to benefit from LADR drugs.
|
$371319 |
$0.75
|
Loading company comparison...
Loading industry trends...
Loading research report...
